28.09.2021 Cannovum AG  DE000A2LQU21

DGAP-News: Cannovum AG expands cannabis wholesale license and enters the active ingredient market


 

DGAP-News: Cannovum AG / Key word(s): Regulatory Approval
Cannovum AG expands cannabis wholesale license and enters the active ingredient market

28.09.2021 / 09:00
The issuer is solely responsible for the content of this announcement.


Cannovum AG (Düsseldorf, Munich, Hamburg, Berlin stock exchanges, gettex: ISIN DE000A2LQU21) is expanding its wholesale license through its subsidiary, Cannovum Health eG. The expansion includes the active ingredient license, which enables the trading of active pharmaceutical ingredients. Cannovum is now authorized to distribute dronabinol, the first cannabis-based active ingredient, to pharmacies.

Active pharmaceutical ingredients are the components of a medication that are responsible for its efficacy. They trigger the essential biochemical process that ensures the medication acts in a specific way in the human body. One of the most important active ingredients of cannabis is THC, which is considered to have the greatest pharmaceutical potential and therapeutic efficacy.

Cannovum's scientific sales force has undergone intensive training with medical professionals, including for the new THC active ingredients, to assist physicians and pharmacists with individual cannabis-based therapies.

With the active ingredient license, Cannovum can now deal with active pharmaceutical ingredients in general and is not limited to dronabinol. In addition, Cannovum already holds the pharmaceutical wholesale licenses, including the GMP license required to map manufacturing steps in Germany.

"We want to improve patient care and that's why we decided to add active substances to our portfolio. Active ingredients are the core element of every medication and indispensable in the effective therapy of patients. We want to give physicians the opportunity to find an effective individual treatment for each of their patients, because every patient deserves the best therapy," says Pia Marten, CEO of Cannovum AG.



28.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
Germany
Phone: +49 (0)30 3982 16360
E-mail: [email protected]
Internet: www.cannovum.com
ISIN: DE000A2LQU21
WKN: A2LQU2
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
EQS News ID: 1236360

 
End of News DGAP News Service

1236360  28.09.2021 

fncls.ssp?fn=show_t_gif&application_id=1236360&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,09 0,00 0,00
EBITDA1,2 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 -55,56 0,00 0,00
EBIT1,4 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 -55,56 0,00 0,00
Jahresüberschuss1 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 -55,56 0,00 0,00
Cashflow1,7 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 0,00 0,00 0,00 -0,05
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: M&B Treuhand

INVESTOR-INFORMATIONEN
©boersengefluester.de
Cannovum
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2LQU2 9,000 20,85
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -915,00
KBV KCV KUV EV/EBITDA
1,81 - 0,00 -694,86
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 07.09.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
62,45% 0,00% 0,00% 0,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Cannovum AG  ISIN: DE000A2LQU21 können Sie bei DGAP abrufen

Handel , A2LQU2 , 27N